CovidChloroV1, Main, Exploration, bibRecord, 000156

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.

Identifieur interne : 000156 ( Main/Exploration ); précédent : 000155; suivant : 000157

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.

Auteurs : Etienne Meriglier [France] ; Claire Rivoisy [France] ; Mojgan Hessamfar [France] ; Noelle Bernard [France] ; Ines Aureau [France] ; Joelle Lapoirie [France] ; Anne Contis [France] ; Frédéric Sacher [France] ; Benjamin Sacristan [France] ; Marin Lahouati [France] ; Stéphane Pedeboscq [France] ; Marie-Anne Vandenhende [France] ; Stéphane Bouchet [France] ; Fabrice Bonnet [France]

Source :

The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2021.

RBID : pubmed:33221868

Descripteurs français

KwdFr :
- Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (sang), Antiviraux (usage thérapeutique), Association de médicaments (MeSH), Darunavir (administration et posologie), Darunavir (effets indésirables), Darunavir (sang), Darunavir (usage thérapeutique), France (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (sang), Hydroxychloroquine (usage thérapeutique), Indice de gravité de la maladie (MeSH), Lopinavir (administration et posologie), Lopinavir (effets indésirables), Lopinavir (sang), Lopinavir (usage thérapeutique), Résultat thérapeutique (MeSH), Syndrome du QT long (induit chimiquement), Syndrome du QT long (épidémiologie), Électrocardiographie (MeSH), Études de cohortes (MeSH).
MESH :
- administration et posologie : Antiviraux, Darunavir, Hydroxychloroquine, Lopinavir.
- effets indésirables : Antiviraux, Darunavir, Hydroxychloroquine, Lopinavir.
- induit chimiquement : Syndrome du QT long.
- sang : Antiviraux, Darunavir, Hydroxychloroquine, Lopinavir.
- usage thérapeutique : Antiviraux, Darunavir, Hydroxychloroquine, Lopinavir.
- épidémiologie : Syndrome du QT long.
- Association de médicaments, France, Humains, Indice de gravité de la maladie, Résultat thérapeutique, Électrocardiographie, Études de cohortes.
Wicri :
- geographic : France.

English descriptors

KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (blood), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (epidemiology), Cohort Studies (MeSH), Darunavir (administration & dosage), Darunavir (adverse effects), Darunavir (blood), Darunavir (therapeutic use), Drug Therapy, Combination (MeSH), Electrocardiography (MeSH), France (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Hydroxychloroquine (blood), Hydroxychloroquine (therapeutic use), Long QT Syndrome (chemically induced), Long QT Syndrome (epidemiology), Lopinavir (administration & dosage), Lopinavir (adverse effects), Lopinavir (blood), Lopinavir (therapeutic use), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , administration & dosage : Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir.
- chemical , adverse effects : Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir.
- chemical , blood : Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir.
- chemical , therapeutic use : Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir.
- geographic : France.
- chemically induced : Long QT Syndrome.
- drug therapy : COVID-19.
- epidemiology : COVID-19, Long QT Syndrome.
- Cohort Studies, Drug Therapy, Combination, Electrocardiography, Humans, SARS-CoV-2, Severity of Illness Index, Treatment Outcome.

Abstract

BACKGROUND

Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection.

OBJECTIVES

To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.

METHODS

This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines.

RESULTS

Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration.

CONCLUSIONS

Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.

DOI: 10.1093/jac/dkaa441
PubMed: 33221868
PubMed Central: PMC7717306

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000791
to stream Main, to step Curation: 000791

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.</title>
<author><name sortKey="Meriglier, Etienne" sort="Meriglier, Etienne" uniqKey="Meriglier E" first="Etienne" last="Meriglier">Etienne Meriglier</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivoisy, Claire" sort="Rivoisy, Claire" uniqKey="Rivoisy C" first="Claire" last="Rivoisy">Claire Rivoisy</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hessamfar, Mojgan" sort="Hessamfar, Mojgan" uniqKey="Hessamfar M" first="Mojgan" last="Hessamfar">Mojgan Hessamfar</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bernard, Noelle" sort="Bernard, Noelle" uniqKey="Bernard N" first="Noelle" last="Bernard">Noelle Bernard</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aureau, Ines" sort="Aureau, Ines" uniqKey="Aureau I" first="Ines" last="Aureau">Ines Aureau</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lapoirie, Joelle" sort="Lapoirie, Joelle" uniqKey="Lapoirie J" first="Joelle" last="Lapoirie">Joelle Lapoirie</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Contis, Anne" sort="Contis, Anne" uniqKey="Contis A" first="Anne" last="Contis">Anne Contis</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sacher, Frederic" sort="Sacher, Frederic" uniqKey="Sacher F" first="Frédéric" last="Sacher">Frédéric Sacher</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>IHU LIRYC, Université de Bordeaux, CHU de Bordeaux, Service de cardiologie, Hôpital Haut-Lévêque, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU LIRYC, Université de Bordeaux, CHU de Bordeaux, Service de cardiologie, Hôpital Haut-Lévêque, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author><name sortKey="Sacristan, Benjamin" sort="Sacristan, Benjamin" uniqKey="Sacristan B" first="Benjamin" last="Sacristan">Benjamin Sacristan</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lahouati, Marin" sort="Lahouati, Marin" uniqKey="Lahouati M" first="Marin" last="Lahouati">Marin Lahouati</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pedeboscq, Stephane" sort="Pedeboscq, Stephane" uniqKey="Pedeboscq S" first="Stéphane" last="Pedeboscq">Stéphane Pedeboscq</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenhende, Marie Anne" sort="Vandenhende, Marie Anne" uniqKey="Vandenhende M" first="Marie-Anne" last="Vandenhende">Marie-Anne Vandenhende</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bouchet, Stephane" sort="Bouchet, Stephane" uniqKey="Bouchet S" first="Stéphane" last="Bouchet">Stéphane Bouchet</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Laboratoire de pharmacologie - toxicologie, Hôpital Pellegrin, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Laboratoire de pharmacologie - toxicologie, Hôpital Pellegrin, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33221868</idno>
<idno type="pmid">33221868</idno>
<idno type="doi">10.1093/jac/dkaa441</idno>
<idno type="pmc">PMC7717306</idno>
<idno type="wicri:Area/Main/Corpus">000791</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000791</idno>
<idno type="wicri:Area/Main/Curation">000791</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000791</idno>
<idno type="wicri:Area/Main/Exploration">000791</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.</title>
<author><name sortKey="Meriglier, Etienne" sort="Meriglier, Etienne" uniqKey="Meriglier E" first="Etienne" last="Meriglier">Etienne Meriglier</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivoisy, Claire" sort="Rivoisy, Claire" uniqKey="Rivoisy C" first="Claire" last="Rivoisy">Claire Rivoisy</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hessamfar, Mojgan" sort="Hessamfar, Mojgan" uniqKey="Hessamfar M" first="Mojgan" last="Hessamfar">Mojgan Hessamfar</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bernard, Noelle" sort="Bernard, Noelle" uniqKey="Bernard N" first="Noelle" last="Bernard">Noelle Bernard</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aureau, Ines" sort="Aureau, Ines" uniqKey="Aureau I" first="Ines" last="Aureau">Ines Aureau</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lapoirie, Joelle" sort="Lapoirie, Joelle" uniqKey="Lapoirie J" first="Joelle" last="Lapoirie">Joelle Lapoirie</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Contis, Anne" sort="Contis, Anne" uniqKey="Contis A" first="Anne" last="Contis">Anne Contis</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sacher, Frederic" sort="Sacher, Frederic" uniqKey="Sacher F" first="Frédéric" last="Sacher">Frédéric Sacher</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>IHU LIRYC, Université de Bordeaux, CHU de Bordeaux, Service de cardiologie, Hôpital Haut-Lévêque, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU LIRYC, Université de Bordeaux, CHU de Bordeaux, Service de cardiologie, Hôpital Haut-Lévêque, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author><name sortKey="Sacristan, Benjamin" sort="Sacristan, Benjamin" uniqKey="Sacristan B" first="Benjamin" last="Sacristan">Benjamin Sacristan</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lahouati, Marin" sort="Lahouati, Marin" uniqKey="Lahouati M" first="Marin" last="Lahouati">Marin Lahouati</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pedeboscq, Stephane" sort="Pedeboscq, Stephane" uniqKey="Pedeboscq S" first="Stéphane" last="Pedeboscq">Stéphane Pedeboscq</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenhende, Marie Anne" sort="Vandenhende, Marie Anne" uniqKey="Vandenhende M" first="Marie-Anne" last="Vandenhende">Marie-Anne Vandenhende</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bouchet, Stephane" sort="Bouchet, Stephane" uniqKey="Bouchet S" first="Stéphane" last="Bouchet">Stéphane Bouchet</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Laboratoire de pharmacologie - toxicologie, Hôpital Pellegrin, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Laboratoire de pharmacologie - toxicologie, Hôpital Pellegrin, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name>
<affiliation wicri:level="3"><nlm:affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. Bordeaux, F-33000 Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of antimicrobial chemotherapy</title>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (blood)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (epidemiology)</term>
<term>Cohort Studies (MeSH)</term>
<term>Darunavir (administration & dosage)</term>
<term>Darunavir (adverse effects)</term>
<term>Darunavir (blood)</term>
<term>Darunavir (therapeutic use)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Electrocardiography (MeSH)</term>
<term>France (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (blood)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Long QT Syndrome (chemically induced)</term>
<term>Long QT Syndrome (epidemiology)</term>
<term>Lopinavir (administration & dosage)</term>
<term>Lopinavir (adverse effects)</term>
<term>Lopinavir (blood)</term>
<term>Lopinavir (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (sang)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association de médicaments (MeSH)</term>
<term>Darunavir (administration et posologie)</term>
<term>Darunavir (effets indésirables)</term>
<term>Darunavir (sang)</term>
<term>Darunavir (usage thérapeutique)</term>
<term>France (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (sang)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Lopinavir (administration et posologie)</term>
<term>Lopinavir (effets indésirables)</term>
<term>Lopinavir (sang)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Syndrome du QT long (induit chimiquement)</term>
<term>Syndrome du QT long (épidémiologie)</term>
<term>Électrocardiographie (MeSH)</term>
<term>Études de cohortes (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antiviral Agents</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Long QT Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term>
<term>Long QT Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Syndrome du QT long</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antiviraux</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Darunavir</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome du QT long</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cohort Studies</term>
<term>Drug Therapy, Combination</term>
<term>Electrocardiography</term>
<term>Humans</term>
<term>SARS-CoV-2</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term>
<term>France</term>
<term>Humains</term>
<term>Indice de gravité de la maladie</term>
<term>Résultat thérapeutique</term>
<term>Électrocardiographie</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b>
</p>
<p>To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33221868</PMID>
<DateCompleted><Year>2021</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>02</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>76</Volume>
<Issue>2</Issue>
<PubDate><Year>2021</Year>
<Month>01</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of antimicrobial chemotherapy</Title>
<ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.</ArticleTitle>
<Pagination><MedlinePgn>482-486</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa441</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection.</AbstractText>
<AbstractText Label="OBJECTIVES">To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.</AbstractText>
<AbstractText Label="METHODS">This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines.</AbstractText>
<AbstractText Label="RESULTS">Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration.</AbstractText>
<AbstractText Label="CONCLUSIONS">Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.</AbstractText>
<CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meriglier</LastName>
<ForeName>Etienne</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rivoisy</LastName>
<ForeName>Claire</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hessamfar</LastName>
<ForeName>Mojgan</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bernard</LastName>
<ForeName>Noelle</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Aureau</LastName>
<ForeName>Ines</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lapoirie</LastName>
<ForeName>Joelle</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Contis</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sacher</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>IHU LIRYC, Université de Bordeaux, CHU de Bordeaux, Service de cardiologie, Hôpital Haut-Lévêque, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sacristan</LastName>
<ForeName>Benjamin</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lahouati</LastName>
<ForeName>Marin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pedeboscq</LastName>
<ForeName>Stéphane</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de pharmacie clinique des médicaments, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vandenhende</LastName>
<ForeName>Marie-Anne</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bouchet</LastName>
<ForeName>Stéphane</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Laboratoire de pharmacologie - toxicologie, Hôpital Pellegrin, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bonnet</LastName>
<ForeName>Fabrice</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>CHU de Bordeaux, Service de médecine interne et maladies infectieuses, Hôpital Saint-André, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Antimicrob Chemother</MedlineTA>
<NlmUniqueID>7513617</NlmUniqueID>
<ISSNLinking>0305-7453</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>YO603Y8113</RegistryNumber>
<NameOfSubstance UI="D000069454">Darunavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069454" MajorTopicYN="N">Darunavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008133" MajorTopicYN="N">Long QT Syndrome</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>20</Hour>
<Minute>42</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33221868</ArticleId>
<ArticleId IdType="pii">5998282</ArticleId>
<ArticleId IdType="doi">10.1093/jac/dkaa441</ArticleId>
<ArticleId IdType="pmc">PMC7717306</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Aquitaine</li>
<li>Nouvelle-Aquitaine</li>
</region>
<settlement><li>Bordeaux</li>
</settlement>
<orgName><li>Université de Bordeaux</li>
</orgName>
</list>
<tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Meriglier, Etienne" sort="Meriglier, Etienne" uniqKey="Meriglier E" first="Etienne" last="Meriglier">Etienne Meriglier</name>
</region>
<name sortKey="Aureau, Ines" sort="Aureau, Ines" uniqKey="Aureau I" first="Ines" last="Aureau">Ines Aureau</name>
<name sortKey="Bernard, Noelle" sort="Bernard, Noelle" uniqKey="Bernard N" first="Noelle" last="Bernard">Noelle Bernard</name>
<name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name>
<name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name>
<name sortKey="Bouchet, Stephane" sort="Bouchet, Stephane" uniqKey="Bouchet S" first="Stéphane" last="Bouchet">Stéphane Bouchet</name>
<name sortKey="Contis, Anne" sort="Contis, Anne" uniqKey="Contis A" first="Anne" last="Contis">Anne Contis</name>
<name sortKey="Hessamfar, Mojgan" sort="Hessamfar, Mojgan" uniqKey="Hessamfar M" first="Mojgan" last="Hessamfar">Mojgan Hessamfar</name>
<name sortKey="Lahouati, Marin" sort="Lahouati, Marin" uniqKey="Lahouati M" first="Marin" last="Lahouati">Marin Lahouati</name>
<name sortKey="Lapoirie, Joelle" sort="Lapoirie, Joelle" uniqKey="Lapoirie J" first="Joelle" last="Lapoirie">Joelle Lapoirie</name>
<name sortKey="Lapoirie, Joelle" sort="Lapoirie, Joelle" uniqKey="Lapoirie J" first="Joelle" last="Lapoirie">Joelle Lapoirie</name>
<name sortKey="Meriglier, Etienne" sort="Meriglier, Etienne" uniqKey="Meriglier E" first="Etienne" last="Meriglier">Etienne Meriglier</name>
<name sortKey="Pedeboscq, Stephane" sort="Pedeboscq, Stephane" uniqKey="Pedeboscq S" first="Stéphane" last="Pedeboscq">Stéphane Pedeboscq</name>
<name sortKey="Rivoisy, Claire" sort="Rivoisy, Claire" uniqKey="Rivoisy C" first="Claire" last="Rivoisy">Claire Rivoisy</name>
<name sortKey="Sacher, Frederic" sort="Sacher, Frederic" uniqKey="Sacher F" first="Frédéric" last="Sacher">Frédéric Sacher</name>
<name sortKey="Sacher, Frederic" sort="Sacher, Frederic" uniqKey="Sacher F" first="Frédéric" last="Sacher">Frédéric Sacher</name>
<name sortKey="Sacristan, Benjamin" sort="Sacristan, Benjamin" uniqKey="Sacristan B" first="Benjamin" last="Sacristan">Benjamin Sacristan</name>
<name sortKey="Vandenhende, Marie Anne" sort="Vandenhende, Marie Anne" uniqKey="Vandenhende M" first="Marie-Anne" last="Vandenhende">Marie-Anne Vandenhende</name>
<name sortKey="Vandenhende, Marie Anne" sort="Vandenhende, Marie Anne" uniqKey="Vandenhende M" first="Marie-Anne" last="Vandenhende">Marie-Anne Vandenhende</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000156 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000156 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33221868
   |texte=   Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33221868" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki